以二甲基亚砜为溶剂,1,4-对二氯苄和吡唑为反应物,微波辐射合成了1,4-二(吡唑基-1-亚甲基)苯。通过实验研究确定最佳合成条件为:微波输出功率为400W、间歇辐射时间为4min、n(吡唑)∶n(对二氯苄)=2.2∶1。最佳条件下产率可达79.6%。经元...以二甲基亚砜为溶剂,1,4-对二氯苄和吡唑为反应物,微波辐射合成了1,4-二(吡唑基-1-亚甲基)苯。通过实验研究确定最佳合成条件为:微波输出功率为400W、间歇辐射时间为4min、n(吡唑)∶n(对二氯苄)=2.2∶1。最佳条件下产率可达79.6%。经元素分析及IR、1 H NMR表征,确认了合成产物结构。展开更多
A new spectrofluorimetric method for determination of trace terbium based on its reaction with 2.6-his-(1'-phenyl-3'-methyl-5'- pyridinediacyl (H_2PMBPP) and N- cetylpyridium bromide (CPB). at an apparent ...A new spectrofluorimetric method for determination of trace terbium based on its reaction with 2.6-his-(1'-phenyl-3'-methyl-5'- pyridinediacyl (H_2PMBPP) and N- cetylpyridium bromide (CPB). at an apparent pH=5.0 provided by a hexamethylenetetramine (5% w/w)-hydrochloric acid buffer,is propesed. The calibration graph is linear in the ran ge from展开更多
Background： The ACTS-GC study had shown postoperative adiuvant therapy with S-1 improved survival of patients with locally advanced gastric cancer. Addition of oxaliplatin to S-1 is considered to be acceptable as one...Background： The ACTS-GC study had shown postoperative adiuvant therapy with S-1 improved survival of patients with locally advanced gastric cancer. Addition of oxaliplatin to S-1 is considered to be acceptable as one of the treatment options for gastric cancer patients after radical gastrectomy with D2 lymph node excision. Methods： We have commenced a randomized phase III trial in December 2016 to evaluate S-I plus oxaliplatin compared with S-1 alone in the adjuvant setting for locally advanced gastric cancer. A total of 564 patients will be accrued from 13 Chinese institutions in two years. The primary endpoint is 3-year relapse-free survival. The secondary endpoints are 5-year overall survival, proportion of patients who complete the postoperative chemotherapy and incidence of adverse events. Ethic and dissemination： The trial has been approved by the institutional review board of each participating institution and it was activated on December, 2016. The enrollment will be finished in December, 2018. Patient＇s follow-up will be ended until December, 2023. Trial registration： ClinicalTrials.gov, identifier： NCT02867839. Registered on August 4, 2016.展开更多
文摘以二甲基亚砜为溶剂,1,4-对二氯苄和吡唑为反应物,微波辐射合成了1,4-二(吡唑基-1-亚甲基)苯。通过实验研究确定最佳合成条件为:微波输出功率为400W、间歇辐射时间为4min、n(吡唑)∶n(对二氯苄)=2.2∶1。最佳条件下产率可达79.6%。经元素分析及IR、1 H NMR表征,确认了合成产物结构。
基金The authors are gratelbl for financial supports IYom the National Natural Science roundation of Chinathe Educational Commiss
文摘A new spectrofluorimetric method for determination of trace terbium based on its reaction with 2.6-his-(1'-phenyl-3'-methyl-5'- pyridinediacyl (H_2PMBPP) and N- cetylpyridium bromide (CPB). at an apparent pH=5.0 provided by a hexamethylenetetramine (5% w/w)-hydrochloric acid buffer,is propesed. The calibration graph is linear in the ran ge from
基金supported by the National Science Foundation of China (No. 81374016 and 81402308)Beijing Municipal Science & Technology Commission (No. D141100000414002)
文摘Background： The ACTS-GC study had shown postoperative adiuvant therapy with S-1 improved survival of patients with locally advanced gastric cancer. Addition of oxaliplatin to S-1 is considered to be acceptable as one of the treatment options for gastric cancer patients after radical gastrectomy with D2 lymph node excision. Methods： We have commenced a randomized phase III trial in December 2016 to evaluate S-I plus oxaliplatin compared with S-1 alone in the adjuvant setting for locally advanced gastric cancer. A total of 564 patients will be accrued from 13 Chinese institutions in two years. The primary endpoint is 3-year relapse-free survival. The secondary endpoints are 5-year overall survival, proportion of patients who complete the postoperative chemotherapy and incidence of adverse events. Ethic and dissemination： The trial has been approved by the institutional review board of each participating institution and it was activated on December, 2016. The enrollment will be finished in December, 2018. Patient＇s follow-up will be ended until December, 2023. Trial registration： ClinicalTrials.gov, identifier： NCT02867839. Registered on August 4, 2016.
